Explainer Report








Feature Importance with Standard Deviation and p-value Significance (WeightedEnsemble_L2)
p < 0.05
Importance
0.12
0.10
0.08
0.06
0.04
0.02
0.00
Dose
age at dx
EGFRI
N Stage
Disease Site
Stage
T Stage
Sex
HPV Combined
Feature


ROC Curve
Test AUROC = 0.93 [0.91, 0.95]
Validation AUROC = 0.97 [0.96, 0.98]
Train AUROC = 0.99 [0.99, 0.99]
Sensitivity
1 - Specificity
Precision-Recall Curve
Test AUC-PR = 0.88 [0.83, 0.93]
Validation AUC-PR = 0.96 [0.93, 0.98]
Train AUC-PR = 0.99 [0.98, 0.99]
Precision
Recall
Test Metrics by Threshold
Test Sensitivity
Test Specificity
Test PPV
Metric
Threshold
Validation Metrics by Threshold
Validation Sensitivity
Validation Specificity
Validation PPV
Metric
Threshold
Train Metrics by Threshold
Train Sensitivity
Train Specificity
Train PPV
Metric
Threshold
Calibration Curve
Test Calibration Curve
Validation Calibration Curve
Train Calibration Curve
Perfect Calibration
Observed Probability
Predicted Probability
Sensitivity/Flag Curve
Test
Validation
Train
Sensitivity
Flag Rate
Histogram of Predicted Probabilities
Test Actual False
Test Actual True
Count
Predicted Probability
Histogram of Predicted Probabilities
Validation Actual False
Validation Actual True
Count
Predicted Probability
Histogram of Predicted Probabilities
Train Actual False
Train Actual True
Count
Predicted Probability


Confusion Matrix
247
47
26
191
Actual
0
1
Predicted
0
1
225
200
175
150
125
100
75
50


Dose
age at dx
N Stage
Stage
EGFRI
Disease Site
T Stage
HPV Combined
Sex
+0.14
+0.14
+0.08
+0.06
+0.05
+0.04
+0.02
+0.02
+0
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
mean(|SHAP value|)


f(x)
Dose
age at dx
N Stage
Stage
EGFRI
Disease Site
T Stage
HPV Combined
Sex
0
20
40
60
80
Instances
0.4792
−0.4792
SHAP value (impact on model output)